A phase III trial evaluating Keytruda monotherapy demonstrated a significant reduction in risk of disease progression in death in microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) unresectable or metastatic colorectal cancer.
The phase III ALEX study demonstrated an increased five-year survival rate with Alecensa (alectinib), compared with crizotinib, in people living with anaplastic lymphoma kinase-positive non-small cell lung cancer.
Xtandi plus androgen deprivation therapy reduced the risk of death in the phase III PROSPER trial evaluating Xtandi (enzalutamide) plus ADT versus placebo plus ADT in men with non-metastatic castration-resistant prostate cancer.
Richard L Schilsky, chief medical officer of the American Society of Clinical Oncology, plans to retire Feb.28, 2021.
ASCO's CancerLinQ has launched a platform for CancerLinQ Discovery, its de-identified real-world cancer data product.
David Rivadeneira was named director of the Northwell Health Cancer Institute at Huntington. For the past seven years, Rivadeneira has led surgical services and colorectal surgery at Huntington Hospital.
MD Anderson Cancer Center and Rakuten Medical Inc. formed a collaboration to develop cancer therapies based on Rakuten Medical's Illuminox technology platform.
FDA publicly posted test performance data from four more antibody, or serology, test kits on open.fda.gov from its independent performance validation study effort with NCI (The Cancer Letter, May 15, 2020).
National Institutes of HealthFrancis S. Collins, NIH director:
The year 2020 will no doubt be recorded as one of the most tumultuous in our nation’s, if not the world’s, history.
